Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Oct;66(4):668–672. doi: 10.1038/bjc.1992.335

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.

R A Fleming 1, G A Milano 1, M C Etienne 1, N Renée 1, A Thyss 1, M Schneider 1, F Demard 1
PMCID: PMC1977433  PMID: 1419604

Abstract

One hundred and eighty seven patients (155 males, 32 females) with histologically proven and previously untreated head and neck cancer were entered in the study. A total of 222 cycles of therapy were analyzed (cisplatin 100 mg m-2 on day 1 and 5-day continuous intravenous infusion of 5-FU 550-1069 mg m-2 day-1, mean 875.5 mg m-2 day-1). Significant interpatient variability for various 5-FU pharmacokinetic parameters was observed including an almost ten-fold range in 5-FU clearance (5-FU Cl, ml min-1 m-2 = 791-7769, mean 2820.7). Log 5-FU Cl was not modified by 5-FU dose (r = -0.1034, P = 0.124, n = 222). Poor linear correlations between log 5-FU Cl and hepatic function tests were observed (respective r and P values for 222 cycles, log AST:0.0526, 0.4365; Log ALT: -0.1167, 0.0842; Log A1K. Phos.:0.154, 0.0214; Log GGT: 0.0652, 0.3436; Log LDH: -0.0984, 0.1563; Log bilirubin: 0.1278, 0.0601). The log 5-FU Cl was also poorly correlated with the serum concentration of various nutritional proteins (respective r and P values for 222 cycles, Albumin: 0.0110, 0.8714; prealbumin: -0.1067, 0.1129; transferrin: 0.0439, 0.5226). Laboratory data including indices of hepatic function and nutritional status cannot account for the interpatient variability in 5-FU disposition.

Full text

PDF
668

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amrein P. C., Weitzman S. A. Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol. 1985 Dec;3(12):1632–1639. doi: 10.1200/JCO.1985.3.12.1632. [DOI] [PubMed] [Google Scholar]
  2. Au J. L., Rustum Y. M., Ledesma E. J., Mittelman A., Creaven P. J. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res. 1982 Jul;42(7):2930–2937. [PubMed] [Google Scholar]
  3. Chirstophidis N., Vajda F. J., Lucas I., Drummer O., Moon W. J., Louis W. J. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet. 1978 Jul-Aug;3(4):330–336. doi: 10.2165/00003088-197803040-00006. [DOI] [PubMed] [Google Scholar]
  4. Christophidis N., Mihaly G., Vajda F., Louis W. Comparison of liquid- and gas-liquid chromatographic assays of 5-fluorouracil in plasma. Clin Chem. 1979 Jan;25(1):83–86. [PubMed] [Google Scholar]
  5. Collins J. M., Dedrick R. L., King F. G., Speyer J. L., Myers C. E. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther. 1980 Aug;28(2):235–246. doi: 10.1038/clpt.1980.156. [DOI] [PubMed] [Google Scholar]
  6. Diasio R. B., Harris B. E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989 Apr;16(4):215–237. doi: 10.2165/00003088-198916040-00002. [DOI] [PubMed] [Google Scholar]
  7. Ensminger W. D., Rosowsky A., Raso V., Levin D. C., Glode M., Come S., Steele G., Frei E., 3rd A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res. 1978 Nov;38(11 Pt 1):3784–3792. [PubMed] [Google Scholar]
  8. Erlichman C., Fine S., Elhakim T. Plasma pharmacokinetics of 5-FU given by continuous infusion with allopurinol. Cancer Treat Rep. 1986 Jul;70(7):903–904. [PubMed] [Google Scholar]
  9. Fleming R. A., Milano G., Thyss A., Etienne M. C., Renée N., Schneider M., Demard F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992 May 15;52(10):2899–2902. [PubMed] [Google Scholar]
  10. Floyd R. A., Hornbeck C. L., Byfield J. E., Griffiths J. C., Frankel S. S. Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases. Drug Intell Clin Pharm. 1982 Sep;16(9):665–667. doi: 10.1177/106002808201600904. [DOI] [PubMed] [Google Scholar]
  11. Goldberg J. A., Kerr D. J., Willmott N., McKillop J. H., McArdle C. S. Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer. 1988 Feb;57(2):186–189. doi: 10.1038/bjc.1988.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kish J., Drelichman A., Jacobs J., Hoschner J., Kinzie J., Loh J., Weaver A., Al-Sarraf M. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1982 Mar;66(3):471–474. [PubMed] [Google Scholar]
  13. McDermott B. J., van den Berg H. W., Murphy R. F. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother Pharmacol. 1982;9(3):173–178. doi: 10.1007/BF00257748. [DOI] [PubMed] [Google Scholar]
  14. Merino O. R., Lindberg R. D., Fletcher G. H. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 1977 Jul;40(1):145–151. doi: 10.1002/1097-0142(197707)40:1<145::aid-cncr2820400124>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  15. Mihranian M. H., Wang Y. M., Daly J. M. Effects of nutritional depletion and repletion on plasma methotrexate pharmacokinetics. Cancer. 1984 Nov 15;54(10):2268–2271. doi: 10.1002/1097-0142(19841115)54:10<2268::aid-cncr2820541034>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  16. Milano G., Cooper E. H., Goligher J. C., Giles G. R., Neville A. M. Serum prealbumin, retinol-binding protein, transferrin, and albumin levels in patients with large bowel cancer. J Natl Cancer Inst. 1978 Sep;61(3):687–691. [PubMed] [Google Scholar]
  17. Milano G., Roman P., Khater R., Frenay M., Renee N., Namer M. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer. 1988 Apr 15;41(4):537–541. doi: 10.1002/ijc.2910410411. [DOI] [PubMed] [Google Scholar]
  18. Nowakowska-Dulawa E. Circadian rhythm of 5-fluorouracil (FU) pharmacokinetics and tolerance. Chronobiologia. 1990 Jan-Mar;17(1):27–35. [PubMed] [Google Scholar]
  19. Santini J., Milano G., Thyss A., Renee N., Viens P., Ayela P., Schneider M., Demard F. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer. 1989 Feb;59(2):287–290. doi: 10.1038/bjc.1989.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Thyss A., Milano G., Renée N., Vallicioni J., Schneider M., Demard F. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol. 1986;16(1):64–66. doi: 10.1007/BF00255288. [DOI] [PubMed] [Google Scholar]
  21. Thyss A., Schneider M., Santini J., Caldani C., Vallicioni J., Chauvel P., Demard F. Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer. 1986 Nov;54(5):755–760. doi: 10.1038/bjc.1986.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Vesell E. S. The model drug approach in clinical pharmacology. Clin Pharmacol Ther. 1991 Sep;50(3):239–248. doi: 10.1038/clpt.1991.132. [DOI] [PubMed] [Google Scholar]
  23. Yeh K. C., Kwan K. C. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm. 1978 Feb;6(1):79–98. doi: 10.1007/BF01066064. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES